DCA

Welcome to the Brand page for “DCA”, which is offered here for Pharmaceutical preparations for the treatment of elevated circulating cholesterol, vascular inflammation, atherosclerosis, cardiovascular disease, diabetes mellitus, infection and/or inflammation in immunosuppressed subjects, cancer, organ transplant rejection and graft-versus-host-disease, bacteremia, sepsis, septic shock, acute respiratory distress syndrome, pain, wounds, respiratory disorders, neurofibromatosis, rheumatoid arthritis, waginer's granulomatosis, kawasaki's disease, lupus erathematosis, midline granuloma, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, psoriasis, pre-leukemias, anemia with excess blasts, and myelodysplastic syndrome;.

Its status is currently believed to be active. Its class is unavailable. “DCA” is believed to be currently owned by “Agennix Incorporated”.